MedEsthetics May/June 2018
Legal, ethical and informed consent considerations when using products off-label.

Using pharmaceuticals “off-label”—that is, in ways that are not specified by the United States Food and Drug Administration (FDA)—is technically legal but somewhat controversial in aesthetic medicine. Decisions regarding off-label usage should be based on current standards of care, the best interest of the patient, and your own training and expertise within the medical field. Following are some...


MedEsthetics May/June 2018

Using pharmaceuticals “off-label”—that is, in ways that are not specified by the...

MedEsthetics May/June 2018

The desire to treat patients of all ages in a one-on-one setting drew Lily Talakoub,...

MedEsthetics May/June 2018 Business Consult

Sexually charged comments and behaviors can destroy workplace morale and spark costly...

MedEsthetics April 2018

It has been more than 15 years since Thermage, the first radiofrequency (RF)-based...


Neck and Decollete Treatment

Alastin Restorative Neck Complex with TriHex Technology was specifically...

Neck Rejuvenation Treatment

Revision Skincare’s new Nectifirm ADVANCED targets the microbiome of the...

Nd:YAG picosecond laser

The PICOCARE from Wontech is a picosecond Nd:YAG laser featuring two...

Salicylic acid treatment

Formulated to clear blemishes and improve acne-prone skin, dm Skincare...


Facebook Ad Leads
By Angela (Miller) Hamilton, Facebook Marketing Expert at ReachLocal With more than 1.71 billion active users on Facebook, social media advertising is an important way for medspas and medical practices to reach local consumers online. Most facilties have a company page and perhaps purchase a few...
Addressing Employee Tardiness
By Paul Edwards, CEO of CEDR HR Solutions There’s nothing more maddening than knowing your patients are due to arrive at your door at any moment, but because one or more of your employees STILL hasn’t shown up for work, you won’t be able to take the patients back right away. Despite the many...
Addition of Nanofat Enhances Fat Graft Neovascularization

Co-transplantation of fat with nanofat promotes neovascularization and improves fat graft survival, according to the results of a mouse study performed by Qian Yu, PhD, et al, of the department of plastic and reconstructive surgery at Shanghai 9th People’s Hospital in Shanghai, China.

The researchers grafted fat under the scalps of nude mice. They added nanofat—prepared via mechanical emulsification and filtration—to the harvested fat in two groups. One group received fat with no nanofat to act as a control. Twelve weeks after transplantation, they dissected the grafted fat and measured graft weight and volume. Capillary density was measured through histological evaluation.

Both groups that underwent co-transplantation of fat with nanofat showed higher graft weight and volume retention and higher capillary density compared to controls. There were no significant differences in outcomes between the two nanofat volumes.
The study was published in the June 2018 issue of Aesthetic Surgery.

Image copyright Getty Images

Hartman Named Chief Commercial Officer of Alastin

ALASTIN Skincare has appointed James P. Hartman to the position of chief commercial officer. Hartman most recently served as vice president and general manager at Solta Medical, a division of Valeant Pharmaceuticals. Prior to Solta, he was VP and U.S. head of aesthetics & OTC at Merz Aesthetics and VP of global marketing and business development at Obagi Medical.

“We are extremely pleased to have Jim join ALASTIN as a key member of the executive team to lead our commercialization activities as we continue the rapid growth of our current products and build our product pipeline,” said Diane S. Goostree, president and CEO of ALASTIN Skincare. “Jim’s extensive operating background in the medical aesthetics space, including experience with energy-based rejuvenating devices, is a natural fit for us as we develop and launch new products and expand our sales force.”

Image: James P. Hartman

Evolus Vows To Move Forward As FDA Fails To Approve Its Neurotoxin

The approval of Evolus’ DWP-450 (prabotulinumtoxinA) has hit a snag, reportedly due to issues at the appointed manufacturing facility. The U.S. Food & Drug Administration issued a complete response letter (CRL) to the company’s biologic license application for DWP-450 outlining concerns that must be addressed before the FDA can approve the new neurotoxin for marketing in the U.S.

In a call to investors and a publicly released statement, the company did not elaborate on the FDA’s concerns other than to note that the deficiencies cited related to Chemistry, Manufacturing, and Controls (CMC) processes, not clinical performance of the product.

“We are pleased with the progress we continue to make with the FDA, and this CRL confirms our confidence in our clinical submission. Deficiencies cited within the CRL are isolated to CMC matters and we expect to respond comprehensively within 90 days,” said David Moatazedi, president and CEO of Evolus. “Overall, we view these updates as positive, which together give us the line of sight necessary to build our commercial infrastructure. We look forward to working closely with the FDA and remain committed to bringing DWP-450 to market by spring 2019.”

ASDS Honored With 14 MarCom Awards

The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.

The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.

The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »

Cellfina Available in US

Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.

Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »

This Issue - January/February 2016